<DOC>
	<DOCNO>NCT01088724</DOCNO>
	<brief_summary>Fludarabine may benefit prevent rejection graft solid organ child chemo-immunotherapy treatment post transplant lymphoproliferative disease ( PTLDs ) .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Doxorubicin Rituximab Treatment Post-transplant Lymphoproliferative Disease ( PTLD )</brief_title>
	<detailed_description>Eligible study patient less 18 year old , present non Burkitt , aggressive , CD20 positive PTLD , solid organ transplant . Induction therapy consist two cycle combination Fludarabine ( 30mg/sqm/day , day 1,2,3 ) , Cyclophosphamide ( 750 mg/sqm/day , day 1 ) , Doxorubicin ( 30 mg/sqm/day , day 1 ) Rituximab ( 375 mg/sqm/day , day 4 ) . Thereafter consolidation therapy give follow : two block stage II III LDH le 500 IU/L ; three block stage III LDH &gt; 500 &lt; 1000 IU/L stage IV LDH &lt; 1000 IU/L ; four block stage III IV LDH &gt; 1000 IU/L . Blocks give modify BFM block use treatment non Hodgkin B-lymphomas , follow : Block 1 : High Dose Methotrexate ( HDMTX ) 1.5 gr/sqm ; Vincristine ( VCR,1.5 mg/sqm ) ; Cytarabine ( 120 150 mg/sqm x4 ) ; Ifosfamide ( 600 mg/sqm/day x5 ) ; VP-16 ( 80 mg/sqm/day x2 ) ; Dexamethasone ( DXM,10 mg/sqm/day 5 ays ) ; Intrathecal Methotrexate-Cytarabine-Methylprednisolone ( TIT ) . Block 2 : HDMTX ( 3 gr/sqm ) ; VCR ( 1.5 mg/sqm ) ; Daunomycin ( 20 mg/sqm/day x2 ) ; Cyclophosphamide ( 160 mg/sqm/day x5 ) ; DXM ( 10 mg/sqm/day x5 ) ; TIT Block 3 : Vindesine ( 3 mg/sqm ) ; Cytarabine ( 3000 mg/sqm q 12 hour x4 ) ; VP-16 ( 100 mg/sqm q 12 hour x4 ) ; DXM ( 20 mg/sqm/day x5 ) ; Block 4 Block 1 . Outcome measure : achievement complete remission induction therapy ; incidence infectious episode ; neurological toxicity ; incidence graft rejection ; duration complete remission .</detailed_description>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Children le 18 year old Non Burkitt , CD20 positive aggressive PTLD Solid organ transplant Burkitt PTLD</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>